PMC:7283670 / 86665-88344 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T294","span":{"begin":1271,"end":1278},"obj":"Body_part"}],"attributes":[{"id":"A294","pred":"fma_id","subj":"T294","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T476","span":{"begin":819,"end":822},"obj":"Disease"},{"id":"T477","span":{"begin":902,"end":905},"obj":"Disease"}],"attributes":[{"id":"A476","pred":"mondo_id","subj":"T476","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A477","pred":"mondo_id","subj":"T477","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"}],"text":"Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T734","span":{"begin":119,"end":125},"obj":"http://www.ebi.ac.uk/efo/EFO_0000825"},{"id":"T735","span":{"begin":328,"end":332},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T736","span":{"begin":453,"end":457},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T737","span":{"begin":549,"end":553},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T738","span":{"begin":657,"end":661},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T739","span":{"begin":737,"end":741},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T740","span":{"begin":850,"end":854},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T741","span":{"begin":933,"end":937},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T742","span":{"begin":1138,"end":1142},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T743","span":{"begin":1217,"end":1221},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T744","span":{"begin":1309,"end":1313},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T745","span":{"begin":1402,"end":1406},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"}],"text":"Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T346","span":{"begin":1271,"end":1278},"obj":"Chemical"}],"attributes":[{"id":"A346","pred":"chebi_id","subj":"T346","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T755","span":{"begin":36,"end":71},"obj":"Sentence"},{"id":"T756","span":{"begin":72,"end":143},"obj":"Sentence"},{"id":"T757","span":{"begin":144,"end":1034},"obj":"Sentence"},{"id":"T758","span":{"begin":1035,"end":1078},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1862","span":{"begin":1269,"end":1278},"obj":"Gene"}],"attributes":[{"id":"A1862","pred":"tao:has_database_id","subj":"1862","obj":"Gene:43740568"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)"}